7-[(2R,5R)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-[(2R,5R)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
• 化学式: C₂₀H₃₂F₂O₅
• 分子量: 390.5
• InChiKey: WGFOBBZOWHGYQH-MVJIGTSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• NOVEL COMPOSITION AND METHOD FOR STABILIZING THE SAME
  申请人：Ueno Ryuji

  公开号：US20080255227A1

  公开（公告）日：2008-10-16

  Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.

  揭示了一种新型组合物，包括一种新型的双环化合物和一种甘油酯，预计具有药理活性。将双环化合物溶解在甘油酯中可以显著提高其稳定性。
• ANTI-CONSTIPATION COMPOSITION
  申请人：UENO Ryuji

  公开号：US20120022152A1

  公开（公告）日：2012-01-26

  An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X 1 and X 2 are preferably both fluorine atoms. The composition can be used to treat constipation with out substantive side-effects, such as stomachache.

  本发明的目的是提供一种抗便秘组合物，其含有卤代双环化合物作为至少为1:1的双环/单环结构比例的活性成分。卤代双环化合物由公式（I）表示：其中X1和X2最好都是氟原子。该组合物可用于治疗便秘，没有实质性的副作用，例如胃痛。
• Novel composition containing a bi-cyclic compound and a glyceride
  申请人：Sucampo AG

  公开号：EP1426361B2

  公开（公告）日：2015-02-25
• Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention
  申请人：Currie Mark G.

  公开号：US20100215779A1

  公开（公告）日：2010-08-26

  Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.
• US8088934B2
  申请人：——

  公开号：US8088934B2

  公开（公告）日：2012-01-03